Abbott affirms progress on St. Jude, Alere acquisitions

money
Abbott CEO
Miles White, Abbott's chairman and CEO

Abbott ($ABT) executives shed little light on the progress of its pursuit of St. Jude Medical ($STJ) and diagnostics maker Alere ($ALR) during the pharma and device giant’s 2Q conference call with analysts.

The $25 billion deal with St. Jude encountered a delay earlier this month when it reported that the FTC had requested both companies provide additional information on the proposed acquisition. The move by the regulatory agency extended the waiting period before the two companies can seal the deal by 30 days. The 30-day wait time won’t begin until both Abbott and St. Jude comply with the request.

Miles White, Abbott’s chairman and CEO, told analysts’s during the call Wednesday that “everything is tracking well,” and he hopes to complete the acquisition of St. Jude before the end of the year.

WEBINAR

Accelerate Clinical Operations Across Sponsors, CROs and Partners With a Best-of-Breed Partner Like Box

Tuesday, March 24 | 11am ET / 8am PT

Learn how Box is a critical force multiplier in the Best-of-Breed application stack with partners like Nintex, DocuSign and Slack in supporting clinical operations for both regulated and non-regulated content.

“I think that will be (a) close call just as we work our way through the administrivia of the FTC's request,” White told analysts. “But I'd say there is no big surprises at all. We're just going to try and complete the work that we've already indicated and everything there is tracking according to plan.”

Though the deal with St. Jude was delayed, the $5.8 billion acquisition of Alere hit a roadblock after the diagnostic company was subpoenaed by the DOJ over questions surrounding its sales practices. In April, the company rejected a request by Abbott to nix the deal for a $50 million breakup fee.

"To be honest, no matter what kind of teeth grinding and gnashing we go through with them… one thing I'm certain of is that they are trying to do everything they can in their way to address the challenges," Miles said.

For the 2Q ended June 30, Abbott reported that net sales rose 3.2% to $5.33 billion, beating analysts' estimate of $5.24 billion. The company, on an adjusted basis, earned 55 cents per share for the period, which bettered the average analyst estimate of 53 cents, according to Thomson Reuters I/B/E/S.

Leerink, a healthcare-focused investment bank, considers Abbott stock as a Market Perform, and said in its outlook for the second half of 2016 for Abbott that despite the upbeat tone of company executives, “we continue to remain on the sidelines for now pending further clarity around integration and execution of the two pending acquisitions and building confidence in ABT's ability to successfully deliver on its projected sales and cost synergy targets.”

-here’s the Abbott earnings release
-check out a transcript of the conference call
-see Leerink’s outlook (pdf)

Read more:
Abbott, St. Jude’s $25B tie-up delayed by FTC request 
Can Abbott afford St. Jude and Alere? Moody’s doubts it 
Alere rejects Abbott’s $50M breakup offer for megamerger deal

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.